Today: 21 May 2026
Ondas stock jumps after rebrand plan, West Palm Beach HQ shift and fresh defense orders
3 January 2026
2 mins read

Ondas stock jumps after rebrand plan, West Palm Beach HQ shift and fresh defense orders

NEW YORK, Jan 2, 2026, 6:37 PM ET — After-hours

  • Ondas Holdings shares rose about 13% in after-hours trading after the company disclosed a planned corporate name change and a headquarters relocation to Florida.
  • A separate SEC filing showed Ondas Networks extended maturities on several notes to Jan. 15, 2026.
  • The company also flagged about $10 million in new autonomous-systems orders disclosed on Dec. 31.

Shares of Ondas Holdings Inc (ONDS) rose 13.1% to $11.02 in after-hours trading on Friday after the company said it has moved its corporate headquarters to West Palm Beach, Florida, and plans to change its corporate name to Ondas Inc. The stock traded between $9.92 and $11.04 earlier in the day and volume was about 136 million shares.

The rebrand and relocation arrive as Ondas tries to sharpen its pitch as a defense and security technology supplier, a theme that can move valuations quickly in smaller drone and counter-drone companies. Investors have been leaning on order flow as a near-term scoreboard.

On Dec. 31, the company said it had received about $10 million in new purchase orders across its autonomous systems portfolio, including counter-UAS and other security products. It also pointed to an initial purchase order expected in January for a large-scale autonomous border-protection program.

Counter-UAS is shorthand for counter-unmanned aircraft systems — technology designed to detect, track or stop drones. Ondas sells autonomous drones and unmanned ground vehicles, or robotic vehicles, through its Ondas Autonomous Systems unit, and private wireless networking equipment through Ondas Networks.

Chairman and Chief Executive Eric Brock said the new name would “better align our corporate identity with the operating platform we have built and the global, dual-use markets we serve.” The company said the name change is expected to take effect in the first quarter of 2026 and that the headquarters move is not expected to disrupt operations. Ondas Holdings Inc.

Headquarters moves and name changes rarely alter demand on their own, but they can shape how investors value a company chasing long-duration government work and bigger institutional checks.

In a separate Form 8-K filed on Friday, Ondas said its Ondas Networks subsidiary signed a letter agreement with noteholders to extend the maturity date of several notes to Jan. 15, 2026. The filing listed convertible and secured notes held by Charles & Potomac Capital and a private investor group.

The maturity extension buys time, but it also keeps the focus on funding as Ondas scales manufacturing and deliveries. Any new financing terms will likely set the tone for the next leg in the stock.

Ondas competes in a crowded market for drones and counter-drone technology that includes defense contractors and specialist drone makers such as AeroVironment and Kratos Defense & Security Solutions. For smaller suppliers, contract timing often drives revenue swings quarter to quarter.

Traders will be watching for confirmation of the January border-protection purchase order the company highlighted, and for updates on the $10 million order book. They will also look for details on when the company expects to complete the corporate name change and any ticker updates.

After Friday’s $9.92-to-$11.04 range, technical traders will be watching whether the stock holds the $10 level when regular trading resumes. A break below that area would put the day’s low back on the radar.

For Monday’s session, the question is whether the burst in volume reflects fresh institutional demand or short-term momentum trading. Either way, Ondas’ next filings and order announcements now carry more weight than the rebrand itself.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention
Previous Story

Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention

Western Digital stock surges nearly 9% to start 2026 — what’s driving WDC now
Next Story

Western Digital stock surges nearly 9% to start 2026 — what’s driving WDC now

Go toTop